Top Markets
Coin of the day
IDL Diagnostics AB (publ) IDL Diagnostics AB (publ)

IDL Diagnostics AB (publ)

IDLDX
Rangering i aksjer #32452
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops... Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Aksjekurs
$0.04367217
Markedsverdi
$10.06M
Endring (1 dag)
3.99%
Endring (1 år)
-23.26%
Land
SE
Handel IDL Diagnostics AB (publ) (IDLDX)

Kategori

P/B-forhold for IDL Diagnostics AB (publ) (IDLDX)
P/B-forhold per 2026 TTM: 0
Ifølge IDL Diagnostics AB (publ) sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for IDL Diagnostics AB (publ) fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
4.1431 -
US
2.7156 -
US
- -
CN
24.3791 -
US
27.366 -
US